81 filings
8-K
ANAB
AnaptysBio Inc
11 Mar 24
Anaptys Announces Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
4:19pm
8-K
ANAB
AnaptysBio Inc
5 Jan 24
Results of Operations and Financial Condition
4:09pm
8-K
ANAB
AnaptysBio Inc
27 Nov 23
Entry into a Material Definitive Agreement
4:17pm
8-K
ANAB
AnaptysBio Inc
2 Nov 23
Anaptys Announces Third Quarter 2023 Financial Results and Provides Business Update
4:18pm
8-K
ANAB
AnaptysBio Inc
25 Oct 23
Regulation FD Disclosure
4:43pm
8-K
4cst aez2ad2mjlyj
10 Oct 23
Regulation FD Disclosure
9:01am
8-K
af1i0fi ns3dv7u1h41
18 Sep 23
Departure of Directors or Certain Officers
4:18pm
8-K
r249jo uzmx
7 Aug 23
AnaptysBio Announces Second Quarter 2023 Financial Results and Provides Business Update
4:18pm
8-K
qyefz1tw4mp2l
15 Jun 23
Submission of Matters to a Vote of Security Holders
5:15pm
8-K
2men9kj7618yy9foz
11 May 23
AnaptysBio Announces First Quarter 2023 Financial Results and Provides Pipeline Update
4:17pm
8-K
6chqz0bzy8gaupdmbm8
6 Apr 23
Departure of Directors or Certain Officers
4:18pm
8-K
ysr9k lbctlcwkfblm19
1 Mar 23
AnaptysBio Announces Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update
4:09pm
8-K
5k2o2
10 Feb 23
Amendments to Articles of Incorporation or Bylaws
4:10pm
8-K
hwszjyfvvev hlmh8s
13 Jan 23
AnaptysBio Announces Stock Repurchase Plan
9:03am
8-K
og2osoylo56l4crian
5 Jan 23
AnaptysBio Announces Portfolio Update Across Best-in-Class Immune Cell Modulating Antibodies
4:12pm
8-K
6ztq3vg
8 Nov 22
AnaptysBio Announces Third Quarter 2022 Financial Results and Provides Pipeline Update
4:08pm
8-K
8ks8qei
12 Sep 22
Entry into a Material Definitive Agreement
7:32am
8-K
eyqz99r
31 Aug 22
AnaptysBio Reports HARP Phase 2 Top-Line Data of Imsidolimab in Moderate-to-Severe Hidradenitis Suppurativa
4:19pm
8-K
6aunu9 0d
8 Aug 22
AnaptysBio Announces Second Quarter 2022 Financial Results and Provides Pipeline Update
4:21pm
8-K
qqx2t7
24 Jun 22
Submission of Matters to a Vote of Security Holders
4:05pm